AU2010313339B2 - Peptide compositions and methods for inhibiting herpesvirus infection - Google Patents

Peptide compositions and methods for inhibiting herpesvirus infection Download PDF

Info

Publication number
AU2010313339B2
AU2010313339B2 AU2010313339A AU2010313339A AU2010313339B2 AU 2010313339 B2 AU2010313339 B2 AU 2010313339B2 AU 2010313339 A AU2010313339 A AU 2010313339A AU 2010313339 A AU2010313339 A AU 2010313339A AU 2010313339 B2 AU2010313339 B2 AU 2010313339B2
Authority
AU
Australia
Prior art keywords
seq
peptide
hcmv
sequence
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010313339A
Other languages
English (en)
Other versions
AU2010313339A1 (en
Inventor
Robert F. Garry
Lilia I. Melnik
Cindy A. Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of AU2010313339A1 publication Critical patent/AU2010313339A1/en
Application granted granted Critical
Publication of AU2010313339B2 publication Critical patent/AU2010313339B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2010313339A 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection Ceased AU2010313339B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28011209P 2009-10-30 2009-10-30
US61/280,112 2009-10-30
PCT/US2010/054743 WO2011053798A2 (en) 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection

Publications (2)

Publication Number Publication Date
AU2010313339A1 AU2010313339A1 (en) 2012-06-07
AU2010313339B2 true AU2010313339B2 (en) 2016-05-26

Family

ID=43923008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010313339A Ceased AU2010313339B2 (en) 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection

Country Status (6)

Country Link
US (2) US8802106B2 (https=)
EP (1) EP2493911B1 (https=)
JP (2) JP2013509432A (https=)
AU (1) AU2010313339B2 (https=)
CA (1) CA2779459A1 (https=)
WO (1) WO2011053798A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
JP6679484B2 (ja) * 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3474887A1 (en) * 2016-06-27 2019-05-01 AiCuris Anti-infective Cures GmbH Hcmv entry inhibitors
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111675752B (zh) * 2020-03-16 2023-07-07 成都奥达生物科技有限公司 一种冠状病毒膜融合抑制剂及其药物用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3211449A1 (en) * 2021-02-24 2022-09-01 Pfizer Inc. Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof
CN115894708B (zh) * 2022-08-16 2023-10-10 青岛大学 一种人巨细胞病毒抗原表位嵌合肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000720A1 (en) * 2001-06-26 2003-01-03 The Council Of The Queensland Institute Of Medical Research Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
US20050260199A1 (en) * 2004-05-12 2005-11-24 Teresa Compton Cytomegalovirus disintegrin-like peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335429C (en) * 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US5831001A (en) * 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
CA2295933A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Compounds and methods for treating and screening viral reactivation
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
FR2818279B1 (fr) * 2000-12-15 2005-02-25 Univ Paris Curie Peptide de la glycoproteine b de l'herpesvirus humain 7 utilisable notamment dans un test serologique elisa
DK2311848T3 (da) * 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
US20090181889A1 (en) * 2006-03-08 2009-07-16 University Of Rochester Compositions and methods for detection and treatment of human herpesvirus (hhv)-6
CN101780277A (zh) * 2009-01-15 2010-07-21 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的免疫原组成物及其使用方法
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000720A1 (en) * 2001-06-26 2003-01-03 The Council Of The Queensland Institute Of Medical Research Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
US20050260199A1 (en) * 2004-05-12 2005-11-24 Teresa Compton Cytomegalovirus disintegrin-like peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UniProt accession Q9WMX1, 1 November 1999 *

Also Published As

Publication number Publication date
US8802106B2 (en) 2014-08-12
CA2779459A1 (en) 2011-05-05
EP2493911A4 (en) 2014-01-01
AU2010313339A1 (en) 2012-06-07
WO2011053798A2 (en) 2011-05-05
EP2493911A2 (en) 2012-09-05
JP2013509432A (ja) 2013-03-14
WO2011053798A3 (en) 2011-09-22
US9434769B2 (en) 2016-09-06
EP2493911B1 (en) 2017-10-18
JP2016128477A (ja) 2016-07-14
JP6209228B2 (ja) 2017-10-04
US20150119318A1 (en) 2015-04-30
US20130005648A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
AU2010313339B2 (en) Peptide compositions and methods for inhibiting herpesvirus infection
Heldwein et al. Entry of herpesviruses into mammalian cells
Vanarsdall et al. PDGF receptor-α does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway
Melnik et al. Peptide inhibition of human cytomegalovirus infection
Bahnamiri et al. Distinct roles of viral US3 and UL13 protein kinases in herpes virus simplex type 1 (HSV-1) nuclear egress
Li et al. Deleting UL49. 5 in duck plague virus causes attachment, entry and spread defects
Dogrammatzis Manipulating the Social Network during Viral Infections
Streck Human cytomegalovirus utilizes ESCRT-III and extracellular vesicles to enhance virus spread
Chi et al. In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus
Sandhu Targeted Modulation of Host Immune Proteins by Human Cytomegalovirus
Lambert Varicella-Zoster virus ORF9p: role in viral envelopment and cell-cell fusion
Zhao TRIM5α is a poxvirus restriction factor: viral evasion strategies and a pathway to antivirals
Henderson A Cytomegalovirus Glycoprotein H-Associated Tropism and Entry (GATE) Complex Enhances Endothelial Cell Infection
EP3945094A1 (en) Replication-deficient adenovirus
Shao Characterization of Epstein-Barr virus BALF0/BALF1 proteins
Strahan The Role of ORF59 in coupling viral transcription and replication
Massaro Interaction of Glycoproteins H/L from human α-herpesviruses with αvβ integrins
KR20220007108A (ko) 헤르페스바이러스과 감염의 치료 또는 예방에 사용하기 위한 펩티드
Gao The Role of HSV-2 UL16 in Nuclear Egress of Capsids
Kalu Pharmacologically-induced cellular stress and herpesvirus replication
Brandt MULTIPLE PEPTIDES HOMOLOGOUS TO HERPES SIMPLEX VIRUS TYPE 1 GLYCOPROTEIN B INHIBIT VIRAL INFECTION 2
Sorem Analysis of the function of cleavage and conformation of Epstein-Barr virus glycoproteins gB and gp42 in membrane fusion
Leiper Characterisation of mutants in the herpes simplex virus-1 ICP27 regulatory protein
Vu Mechanisms of nuclear lamina disruption and regulation of nuclear budding of herpes simplex virus type-1
Eisfeld Viral and cellular targets for the varicella-zoster virus ORF66 protein kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired